Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » CombiMatrix Launches Lab-Made Autism Risk Dx; Firm Evaluating FDA Submission

CombiMatrix Launches Lab-Made Autism Risk Dx; Firm Evaluating FDA Submission

Jan 02, 2008
Premium
Having completed the clinical validation of its ATScan test for autism spectrum disorder, CombiMatrix last month announced that it would make the technology available through its CLIA labs.
 
CombiMatrix said that the launch of the microarray-based test is timely since it follows the American Academy of Pediatrics’ recently updated guidelines recommending all children be screened at least twice for autism before the age of two.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

What's Popular?

In Diagnostics

  1. Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.